CCDC57 Inhibitors

CCDC57 inhibitors, while not directly targeting CCDC57, exert their influence on a range of cellular processes and pathways that may involve this protein. Aphidicolin's action, for instance, is to inhibit DNA replication by targeting DNA polymerases alpha and delta, which could impact the replication-associated functions of CCDC57. Camptothecin's stabilization of the DNA-topoisomerase I complex leads to interference with both DNA replication and transcription, processes in which CCDC57 may be involved. Etoposide, by inhibiting DNA topoisomerase II, could affect DNA decatenation and the resolution of DNA tangles, possibly disrupting the normal function of CCDC57.

Mitomycin C forms DNA crosslinks that can disrupt replication and repair mechanisms, which CCDC57 could be associated with, while Hydroxyurea inhibits ribonucleotide reductase, leading to reduced DNA synthesis where CCDC57 might function. Olaparib, a PARP inhibitor, impedes the DNA repair process and may therefore influence CCDC57's recruitment or function in DNA repair. The inhibition of ATR kinase affects the DNA damage response pathways, which could involve CCDC57, and similarly, CHK1 inhibitors disrupt cell cycle checkpoints, which may also implicate the protein's role. PIKK inhibitors target a family of kinases involved in DNA damage repair and replication, potentially impacting CCDC57's function in these processes. Cisplatin, by forming DNA adducts, disrupts DNA replication and repair mechanisms, which could affect CCDC57's role. ATM kinase inhibitors, such as Ku-55933, influence the DNA damage repair pathways, possibly altering CCDC57's activity. NU7441's inhibition of DNA-PK affects DNA double-strand break repair, another process where CCDC57 could be implicated.